The transcription factor ETS1 in lymphomas: friend or foe?

References

• Watson DK, McWilliams MJ, Lapis P, et al. Mammalian ets-1 and ets-2 genes encode highly conserved proteins. Proc Natl Acad Sci USA 1988;85:7862–7866.
   PubMed Web of Science ®Google Scholar
• Watson DK, McWilliams-Smith MJ, Kozak C, et al. Conserved chromosomal positions of dual domains of the ets protooncogene in cats, mice, and humans. Proc Natl Acad Sci USA 1986;83:1792–1796.
   PubMed Web of Science ®Google Scholar
• Sharrocks AD. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2001;2:827–837.
   PubMed Web of Science ®Google Scholar
• Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene 2003;303:11–34.
   PubMed Web of Science ®Google Scholar
• Hollenhorst PC, McIntosh LP, Graves BJ. Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem 2011;80:437–471.
   PubMed Web of Science ®Google Scholar
• Hollenhorst PC, Shah AA, Hopkins C, et al. Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. Genes Dev 2007;21:1882–1894.
   PubMed Web of Science ®Google Scholar
• Liu H, Holm M, Xie XQ, et al. AML1/Runx1 recruits calcineurin to regulate granulocyte macrophage colony-stimulating factor by Ets1 activation. J Biol Chem 2004;279:29398–29408.
   PubMed Web of Science ®Google Scholar
• Arman M, Aguilera-Montilla N, Mas V, et al. The human CD6 gene is transcriptionally regulated by RUNX and Ets transcription factors in T cells. Mol Immunol 2009;46:2226–2235.
   PubMed Web of Science ®Google Scholar
• Pufall MA, Graves BJ. Ets-1 flips for new partner Pax-5. Structure 2002;10:11–14.
   PubMed Web of Science ®Google Scholar
• Kang HS, Nelson ML, Mackereth CD, et al. Identification and structural characterization of a CBP/p300-binding domain from the ETS family transcription factor GABP alpha. J Mol Biol 2008;377: 636–646.
   PubMed Web of Science ®Google Scholar
• Li R, Pei H, Watson DK. Regulation of Ets function by protein-protein interactions. Oncogene 2000;19:6514–6523.
   PubMed Web of Science ®Google Scholar
• Verger A, Duterque-Coquillaud M. When Ets transcription factors meet their partners. Bioessays 2002;24:362–370.
   PubMed Web of Science ®Google Scholar
• Graves BJ, Petersen JM. Specificity within the ets family of transcription factors. Adv Cancer Res 1998;75:1–55.
   PubMed Web of Science ®Google Scholar
• Seth A, Robinson L, Thompson DM, et al. Transactivation of GATA-1 promoter with ETS1, ETS2 and ERGB/Hu-FLI-1 proteins: stabilization of the ETS1 protein binding on GATA-1 promoter sequences by monoclonal antibody. Oncogene 1993;8:1783–1790.
   PubMed Web of Science ®Google Scholar
• Kramer B, Wiegmann K, Kronke M. Regulation of the human TNF promoter by the transcription factor Ets. J Biol Chem 1995;270: 6577–6583.
   PubMed Web of Science ®Google Scholar
• Venanzoni MC, Robinson LR, Hodge DR, et al. ETS1 and ETS2 in p53 regulation: spatial separation of ETS binding sites (EBS) modulate protein: DNA interaction. Oncogene 1996;12:1199–1204.
   PubMed Web of Science ®Google Scholar
• Lambert PF, Ludford-Menting MJ, Deacon NJ, et al. The nfkb1 promoter is controlled by proteins of the Ets family. Mol Biol Cell 1997;8:313–323.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Itoh K, Togano T, et al. Ets-1 activates overexpression of JunB and CD30 in Hodgkin's lymphoma and anaplastic large-cell lymphoma. Am J Pathol 2012;180:831–838.
   PubMed Web of Science ®Google Scholar
• Yunis JJ, Jones C, Madden MT, et al. Gene order, amplification, and rearrangement of chromosome band 11q23 in hematologic malignancies. Genomics 1989;5:84–90.
   PubMed Web of Science ®Google Scholar
• Rovigatti U, Watson DK, Yunis JJ. Amplification and rearrangement of Hu-ets-1 in leukemia and lymphoma with involvement of 11q23. Science 1986;232:398–400.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011;43:830–837.
   PubMed Web of Science ®Google Scholar
• Bonetti P, Testoni M, Scandurra M, et al. Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. Blood 2013;122:2233–2241.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011;476:298–303.
   PubMed Web of Science ®Google Scholar
• Salaverria I, Martin-Guerrero I, Wagener R, et al. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood 2014;123:1187–1198.
   PubMed Web of Science ®Google Scholar
• Overbeck BM, Martin-Subero JI, Ammerpohl O, et al. ETS1 encoding a transcription factor involved in B-cell differentiation is recurrently deleted and down-regulated in classical Hodgkin's lymphoma. Haematologica 2012;97:1612–1614.
   PubMed Web of Science ®Google Scholar
• Schwering I, Brauninger A, Klein U, et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003;101:1505–1512.
   PubMed Web of Science ®Google Scholar
• Jonsen MD, Petersen JM, Xu QP, et al. Characterization of the cooperative function of inhibitory sequences in Ets-1. Mol Cell Biol 1996;16:2065–2073.
   PubMed Web of Science ®Google Scholar
• Pufall MA, Lee GM, Nelson ML, et al. Variable control of Ets-1 DNA binding by multiple phosphates in an unstructured region. Science 2005;309:142–145.
   PubMed Web of Science ®Google Scholar
• Fleischman LF, Holtzclaw L, Russell JT, et al. ets-1 in astrocytes: expression and transmitter-evoked phosphorylation. Mol Cell Biol 1995;15:925–931.
   PubMed Web of Science ®Google Scholar
• Kim WY, Sieweke M, Ogawa E, et al. Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains. EMBO J 1999;18:1609–1620.
   PubMed Web of Science ®Google Scholar
• Fitzsimmons D, Lukin K, Lutz R, et al. Highly cooperative recruitment of Ets-1 and release of autoinhibition by Pax5. J Mol Biol 2009;392:452–464.
   PubMed Web of Science ®Google Scholar
• Goetz TL, Gu TL, Speck NA, et al. Auto-inhibition of Ets-1 is counteracted by DNA binding cooperativity with core-binding factor alpha2. Mol Cell Biol 2000;20:81–90.
   PubMed Web of Science ®Google Scholar
• Tian G, Erman B, Ishii H, et al. Transcriptional activation by ETS and leucine zipper-containing basic helix-loop-helix proteins. Mol Cell Biol 1999;19:2946–2957.
   PubMed Web of Science ®Google Scholar
• Foulds CE, Nelson ML, Blaszczak AG, et al. Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment. Mol Cell Biol 2004;24:10954–10964.
   PubMed Web of Science ®Google Scholar
• Wasylyk B, Hagman J, Gutierrez-Hartmann A. Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends Biochem Sci 1998;23:213–216.
   PubMed Web of Science ®Google Scholar
• Yang C, Shapiro LH, Rivera M, et al. A role for CREB binding protein and p300 transcriptional coactivators in Ets-1 transactivation functions. Mol Cell Biol 1998;18:2218–2229.
   PubMed Web of Science ®Google Scholar
• Laitem C, Leprivier G, Choul-Li S, et al. Ets-1 p27: a novel Ets-1 isoform with dominant-negative effects on the transcriptional properties and the subcellular localization of Ets-1 p51. Oncogene 2009;28:2087–2099.
   PubMed Web of Science ®Google Scholar
• Ji Z, Degerny C, Vintonenko N, et al. Regulation of the Ets-1 transcription factor by sumoylation and ubiquitinylation. Oncogene 2007;26:395–406.
   PubMed Web of Science ®Google Scholar
• Hahn SL, Wasylyk B, Criqui-Filipe P. Modulation of ETS-1 transcriptional activity by huUBC9, a ubiquitin-conjugating enzyme. Oncogene 1997;15:1489–1495.
   PubMed Web of Science ®Google Scholar
• Dong Z. Acetylation of Ets-1 is the key to chromatin remodeling for miR-192 expression. Sci Signal 2013;6:pe21.
   Web of Science ®Google Scholar
• Nishida T, Terashima M, Fukami K. PIASy-mediated repression of the Ets-1 is independent of its sumoylation. Biochem Biophys Res Commun 2006;345:1536–1546.
   PubMed Web of Science ®Google Scholar
• Kato M, Dang V, Wang M, et al. TGF-beta induces acetylation of chromatin and of Ets-1 to alleviate repression of miR-192 in diabetic nephropathy. Sci Signal 2013;6:ra43.
   Web of Science ®Google Scholar
• Dittmer J. The biology of the Ets1 proto-oncogene. Mol Cancer 2003;2:29.
   PubMedGoogle Scholar
• Truong AH, Ben-David Y. The role of Fli-1 in normal cell function and malignant transformation. Oncogene 2000;19: 6482–6489.
   PubMed Web of Science ®Google Scholar
• Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010;28:3360–3365.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009;114:3533–3537.
   PubMed Web of Science ®Google Scholar
• Dang CV. MYC on the path to cancer. Cell 2012;149:22–35.
   PubMed Web of Science ®Google Scholar
• Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146: 904–917.
   PubMed Web of Science ®Google Scholar
• Mertz JA, Conery AR, Bryant BM, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 2011;108:16669–16674.
   PubMed Web of Science ®Google Scholar
• Valera A, Lopez-Guillermo A, Cardesa-Salzmann T, et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica 2013;98:1554–1562.
   PubMed Web of Science ®Google Scholar
• Cuccuini W, Briere J, Mounier N, et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 2012;119:4619–4624.
   PubMed Web of Science ®Google Scholar
• Dittmer J. The biology of the Ets1 proto-oncogene. Mol Cancer 2003;2:29.
   PubMedGoogle Scholar
• Lincoln DW 2nd, Bove K. The transcription factor Ets-1 in breast cancer. Front Biosci 2005;10:506–511.
   PubMed Web of Science ®Google Scholar
• Seth A, Watson DK, Blair DG, et al. c-ets-2 protooncogene has mitogenic and oncogenic activity. Proc Natl Acad Sci USA 1989;86:7833–7837.
   PubMed Web of Science ®Google Scholar
• Hart AH, Corrick CM, Tymms MJ, et al. Human ERG is a proto-oncogene with mitogenic and transforming activity. Oncogene 1995;10:1423–1430.
   PubMed Web of Science ®Google Scholar
• Wasylyk C, Gutman A, Nicholson R, et al. The c-Ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins. EMBO J 1991;10: 1127–1134.
   PubMed Web of Science ®Google Scholar
• Turque N, Buttice G, Beuscart A, et al. Hydrocortisone modulates the expression of c-ets-1 and 72 kDa type IV collagenase in chicken dermis during early feather morphogenesis. Int J Dev Biol 1997;41: 103–109.
   PubMed Web of Science ®Google Scholar
• Watabe T, Yoshida K, Shindoh M, et al. The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int J Cancer 1998;77:128–137.
   PubMed Web of Science ®Google Scholar
• Jayaraman G, Srinivas R, Duggan C, et al. p300/cAMP-responsive element-binding protein interactions with ets-1 and ets-2 in the transcriptional activation of the human stromelysin promoter. J Biol Chem 1999;274:17342–17352.
   PubMed Web of Science ®Google Scholar
• Takai N, Ueda T, Nishida M, et al. The relationship between oncogene expression and clinical outcome in endometrial carcinoma. Curr Cancer Drug Targets 2004;4:511–520.
   PubMed Web of Science ®Google Scholar
• Davidson B, Reich R, Goldberg I, et al. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma. Clin Cancer Res 2001;7:551–557.
   PubMed Web of Science ®Google Scholar
• Chen Z, Fisher RJ, Riggs CW, et al. Inhibition of vascular endothelial growth factor-induced endothelial cell migration by ETS1 antisense oligonucleotides. Cancer Res 1997;57:2013–2019.
   PubMed Web of Science ®Google Scholar
• Wakiya K, Begue A, Stehelin D, et al. A cAMP response element and an Ets motif are involved in the transcriptional regulation of flt-1 tyrosine kinase (vascular endothelial growth factor receptor 1) gene. J Biol Chem 1996;271:30823–30828.
   PubMed Web of Science ®Google Scholar
• Kappel A, Schlaeger TM, Flamme I, et al. Role of SCL/Tal-1, GATA, and ets transcription factor binding sites for the regulation of flk-1 expression during murine vascular development. Blood 2000;96:3078–3085.
   PubMed Web of Science ®Google Scholar
• Verschoor ML, Wilson LA, Verschoor CP, et al. Ets-1 regulates energy metabolism in cancer cells. PLoS One 2010;5:e13565.
   PubMed Web of Science ®Google Scholar
• Hahne JC, Okuducu AF, Sahin A, et al. The transcription factor ETS-1: its role in tumour development and strategies for its inhibition. Mini Rev Med Chem 2008;8:1095–1105.
   PubMed Web of Science ®Google Scholar
• Piva R, Pellegrino E, Mattioli M, et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest 2006;116:3171–3182.
   PubMed Web of Science ®Google Scholar
• Ho IC, Bhat NK, Gottschalk LR, et al. Sequence-specific binding of human Ets-1 to the T cell receptor alpha gene enhancer. Science 1990;250:814–818.
   PubMed Web of Science ®Google Scholar
• Mayall TP, Sheridan PL, Montminy MR, et al. Distinct roles for P-CREB and LEF-1 in TCR alpha enhancer assembly and activation on chromatin templates in vitro. Genes Dev 1997;11:887–899.
   PubMed Web of Science ®Google Scholar
• Wotton D, Prosser HM, Owen MJ. Regulation of human T cell receptor beta gene expression by Ets-1. Leukemia 1993; 7(Suppl. 2):S55–S60.
   PubMedGoogle Scholar
• Halle JP, Haus-Seuffert P, Woltering C, et al. A conserved tissue-specific structure at a human T-cell receptor beta-chain core promoter. Mol Cell Biol 1997;17:4220–4229.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102:15545–15550.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Meyer PN, Smith LM, et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res 2011;17:7785–7795.
   PubMed Web of Science ®Google Scholar
• Thomas RS, Tymms MJ, Seth A, et al. ETS1 transactivates the human GM-CSF promoter in Jurkat T cells stimulated with PMA and ionomycin. Oncogene 1995;11:2135–2143.
   PubMed Web of Science ®Google Scholar
• Nimer SD, Zhang W, Kwan K, et al. Adjacent, cooperative elements form a strong, constitutive enhancer in the human granulocyte-macrophage colony-stimulating factor gene. Blood 1996;87:3694–3703.
   PubMed Web of Science ®Google Scholar
• Thomas RS, Tymms MJ, McKinlay LH, et al. ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter. Oncogene 1997;14:2845–2855.
   PubMed Web of Science ®Google Scholar
• McKinlay LH, Tymms MJ, Thomas RS, et al. The role of Ets-1 in mast cell granulocyte-macrophage colony-stimulating factor expression and activation. J Immunol 1998;161:4098–4105.
   PubMed Web of Science ®Google Scholar
• Boerma EG, Siebert R, Kluin PM, et al. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leukemia 2009;23:225–234.
   PubMed Web of Science ®Google Scholar
• Davar D, Tarhini AA, Kirkwood JM. Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. Clin Dermatol 2013;31:237–250.
   PubMed Web of Science ®Google Scholar
• Blumenthal SG, Aichele G, Wirth T, et al. Regulation of the human interleukin-5 promoter by Ets transcription factors. Ets1 and Ets2, but not Elf-1, cooperate with GATA3 and HTLV-I Tax1. J Biol Chem 1999;274:12910–12916.
   PubMed Web of Science ®Google Scholar
• Drake CG. Combination immunotherapy approaches. Ann Oncol 2012;23(Suppl. 8):viii41–viii46.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Kalos M, Schaer DA, et al. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 2013;19: 1009–1020.
   PubMed Web of Science ®Google Scholar
• Erman B, Sen R. Context dependent transactivation domains activate the immunoglobulin mu heavy chain gene enhancer. EMBO J 1996;15:4665–4675.
   PubMed Web of Science ®Google Scholar
• Nelsen B, Tian G, Erman B, et al. Regulation of lymphoid-specific immunoglobulin mu heavy chain gene enhancer by ETS-domain proteins. Science 1993;261:82–86.
   PubMed Web of Science ®Google Scholar
• Rao E, Dang W, Tian G, et al. A three-protein-DNA complex on a B cell-specific domain of the immunoglobulin mu heavy chain gene enhancer. J Biol Chem 1997;272:6722–6732.
   PubMed Web of Science ®Google Scholar
• Rivera RR, Stuiver MH, Steenbergen R, et al. Ets proteins: new factors that regulate immunoglobulin heavy-chain gene expression. Mol Cell Biol 1993;13:7163–7169.
   PubMed Web of Science ®Google Scholar
• John SA, Clements JL, Russell LM, et al. Ets-1 regulates plasma cell differentiation by interfering with the activity of the transcription factor Blimp-1. J Biol Chem 2008;283:951–962.
   PubMed Web of Science ®Google Scholar
• Wang D, John SA, Clements JL, et al. Ets-1 deficiency leads to altered B cell differentiation, hyperresponsiveness to TLR9 and autoimmune disease. Int Immunol 2005;17:1179–1191.
   PubMed Web of Science ®Google Scholar
• Calado DP, Zhang B, Srinivasan L, et al. Constitutive canonical NF-kappaB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell 2010;18:580–589.
   PubMed Web of Science ®Google Scholar
• Mandelbaum J, Bhagat G, Tang H, et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 2010;18:568–579.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Compagno M, Houldsworth J, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 2006;203:311–317.
   PubMed Web of Science ®Google Scholar
• Eyquem S, Chemin K, Fasseu M, et al. The development of early and mature B cells is impaired in mice deficient for the Ets-1 transcription factor. Eur J Immunol 2004;34:3187–3196.
   PubMed Web of Science ®Google Scholar